Basilea Pharmaceutica AG: Basilea receives request to place repayment of CHF 48 million from capital contribution reserve on the agenda of the ordinary general meeting of shareholders

Basilea Pharmaceutica AG / Basilea receives request to place repayment of CHF 48 million from capital contribution reserve on the agenda of the ordinary general meeting of shareholders . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Basel, Switzerland, February 22, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN) has received a request from one of its shareholders, HBM Healthcare Investments (Cayman) Ltd., which holds more than 20% of Basilea's shares, to place the repayment of CHF 5.00 per registered share from the company's capital contribution reserve on the agenda of Basilea's upcoming ordinary general meeting of shareholders, for a total of approximately CHF 48 million.

Basilea's board of directors will carefully evaluate the request.

Basilea's ordinary general meeting of shareholders is scheduled for April 9, 2013. The deadline for registration in the share register to vote at the ordinary general meeting of shareholders is March 28, 2013.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Media Relations	Investor Relations
Peer Nils Schröder, Ph.D. Head Public Relations & Corporate Communications [phone] [e-mail] (mailto:[e-mail])	Barbara Zink, Ph.D., MBA Head Corporate Development [phone] [e-mail] (mailto:[e-mail])

This press release can be downloaded from www.basilea.com (http://www.basilea.com).

Press release (PDF) (http://hugin.info/134390/R/1680620/549123.pdf)

---

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE

HUG#1680620

--- End of Message ---

Basilea Pharmaceutica AG
Grenzacherstrasse 487
P.O Box Basel Switzerland


Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;